In light of the successful application of anti‐PD‐1/PD‐L1 immunotherapy in solid tumors,7 clinical trials of anti‐PD‐1/PD‐L1 agents have been carried out in patients with DLBCL,13 and accurate evaluation of PD‐L1 status has become a major challenge in DLBCL. This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.